Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology

May 22, 2022

The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.

The Top 5 Biosimilar Articles for the Week of May 16
Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market
Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
Teva’s Lucentis Biosimilar Gains UK Approval